The estimated Net Worth of Laura Shawver is at least $2.28 millió dollars as of 5 August 2022. Dr Shawver owns over 78,740 units of Silverback Therapeutics stock worth over $1,492,401 and over the last 12 years he sold SBTX stock worth over $0. In addition, he makes $786,653 as CEO & Director at Silverback Therapeutics.
Dr has made over 2 trades of the Silverback Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 78,740 units of SBTX stock worth $100,000 on 5 August 2022.
The largest trade he's ever made was exercising 78,740 units of Silverback Therapeutics stock on 5 August 2022 worth over $100,000. On average, Dr trades about 6,102 units every 76 days since 2012. As of 5 August 2022 he still owns at least 254,242 units of Silverback Therapeutics stock.
You can see the complete history of Dr Shawver stock trades at the bottom of the page.
Dr. Laura K. Shawver is the CEO & Director at Silverback Therapeutics.
As the CEO & Director of Silverback Therapeutics, the total compensation of Dr Shawver at Silverback Therapeutics is $786,653. There are no executives at Silverback Therapeutics getting paid more.
Dr Shawver is 63, he's been the CEO & Director of Silverback Therapeutics since . There are no older and 4 younger executives at Silverback Therapeutics.
Laura's mailing address filed with the SEC is C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Silverback Therapeutics have traded over $0 worth of Silverback Therapeutics stock and bought 2,785,936 units worth $58,491,063 . The most active insiders traders include Peter A. Thompson, Thilo Schroeder és Advisors Llc Orbi Med Capit.... On average, Silverback Therapeutics executives and independent directors trade stock every 60 days with the average trade being worth of $1,681,567. The most recent stock trade was executed by Laura Shawver on 5 August 2022, trading 78,740 units of SBTX stock currently worth $100,000.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics executives and other stock owners filed with the SEC include: